Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year (ERASURE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01365455
First received: June 1, 2011
Last updated: May 7, 2015
Last verified: May 2015
  Purpose

This study will assess the safety and efficacy of secukinumab compared to placebo in patients that have moderate to severe, chronic, plaque-type psoriasis.


Condition Intervention Phase
Moderate to Severe Plaque-type Psoriasis
Drug: secukinumab 150 mg
Drug: placebo to secukinumab 150 mg
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Percentage of Participants Who Achieved >75 or Higher (Psoriasis Area and Severity Index) PASI Score at 12 Weeks [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is the current benchmark of primary endpoints for most clinical trials of psoriasis. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

  • Percentage of Participants Who Achieved (Investigator's Global Assessment) IGA Score of 0 or 1 [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1. IGA score of 0 or 1 as an indicator of efficacy.


Secondary Outcome Measures:
  • Percentage of Participants Who Achieved a PASI (Psoriasis Area and Severity Index) Score of 90 or Better at Week 12 [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 90 was defined as participants who achievied ≥ 90% improvement from baseline.

  • Number of Participants That Maintained the Psoriasis Area and Severity Index (PASI) 75 Response at 52 Weeks of Treatment for Participants Who Were PASI 75 Responders at Week 12 [ Time Frame: 12 and 52 weeks ] [ Designated as safety issue: Yes ]
    PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

  • Number of Participants That Maintained the IGA Mod 2011 0 or 1 Response at 52 Weeks of Treatment for Participants Who Were IGA Mod 2011 0 or 1 Responders at Week 12 [ Time Frame: 12 and 52 weeks ] [ Designated as safety issue: No ]
    The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1.

  • Change From Baseline to Week 12 in Psoriasis Symptom Diary Items Itching, Pain and Scaling in AIN457 vs Placebo [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    The Psoriasis Symptom Diary©, a 16-item patient reported outcome (PRO) measure developed and validated in accordance with the FDA PRO Guidance (FDA Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, 2009), demonstrated favorable psychometric properties and usefulness for treatment efficacy evaluation alongside other measures of disease severity in clinical trials for chronic plaque psoriasis.Weekly averages will be derived for each of the 16 questions of the Psoriasis Diary up to Week 12. A weekly average is the sum of the scored item over the course of the study week divided by the number of days on which the item was completed and will be set to missing if four or more daily assessments were missing of the corresponding question. A reduction in score from baseline shows efficacy. Each question has a score of 0 (no symptoms) up to 10 (Severe symptoms)

  • Percentage of Participants Achieving PASI 50/75/90/100 Response or IGA 0 or 1 Response up to 12 Weeks Induction Period [ Time Frame: Week 1,2,3,4,8,12, ] [ Designated as safety issue: No ]
    PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (max). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.

  • Percentage of Participants Achieving PASI 50/75/90/100 Response or IGA 0 or 1 Response Maintenance Period After Week 12 to Week 52 [ Time Frame: Week 13,14,15,16,20,24,28,32,36,40,44,48,52 ] [ Designated as safety issue: No ]
    PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (max). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.

  • Mean Percent Change From Baseline in PASI Scores up to Week 12 - Induction Period [ Time Frame: Baseline, Week 1,2,3,4,8,12, ] [ Designated as safety issue: No ]
    PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement.

  • Mean Percent Change From Baseline in PASI Scores Maintenance Period After Week 12 to Week 52 [ Time Frame: Week 13,14,15,16,20,24,28,32,36,40,44,48,52 ] [ Designated as safety issue: No ]
    PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement.

  • Percentage of Participants in Each IGA Mod 2011 Score Category up to Week 12 - Induction Period [ Time Frame: Baseline, Week 1,2,3,4,8,12, ] [ Designated as safety issue: No ]
    The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.

  • Percentage of Participants in Each IGA Mod 2011 Score Category Maintenance Period After Week 12 to Week 52 [ Time Frame: Week 13,14,15,16,20,24,28,32,36,40,44,48,52 ] [ Designated as safety issue: No ]
    The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.

  • Time to PASI 75 Response up to 12 Weeks [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (max). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 75 was defined as participants achieving ≥ 75% improvement from baseline.

  • Mean Percent Change From Baseline in EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D) Health State Assessment (From 0 to 100) Induction Period [ Time Frame: Baseline, Week 4,8, 12 ] [ Designated as safety issue: No ]
    The EQ-5D is an instrument used to assess a participant's health status. The instrument includes a descriptive profile and a visual analog scale (VAS). The descriptive profile includes 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension had 3 response levels: no problems, some problems and severe problems. The VAS is a vertical scale that assesses the health status from 0 (worst possible health state) to 100 (best possible health state). This outcome measures the percent change in VAS score. Positive mean percent changes indicate improvement.

  • Mean Percent Change From Baseline in EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D) Health State Assessment (From 0 to 100) Maintenance Period [ Time Frame: Week 12, 24, 36, 52 ] [ Designated as safety issue: No ]
    The EQ-5D is an instrument used to assess a participant's health status. The instrument includes a descriptive profile and a visual analog scale (VAS). The descriptive profile includes 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension had 3 response levels: no problems, some problems and severe problems. The VAS is a vertical scale that assesses the health status from 0 (worst possible health state) to 100 (best possible health state). This outcome measures the percent change in VAS score. Positive mean percent changes indicate improvement.

  • Percentage Changes in the Dermatology Life Quality Index (DLQI) During Induction Period [ Time Frame: Baseline, Week 4, 8 & 12 ] [ Designated as safety issue: No ]
    The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.

  • Percentage Changes in the Dermatology Life Quality Index (DLQI) During Maintenance Period [ Time Frame: Week 12,24, 36 & 52 ] [ Designated as safety issue: No ]
    The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.

  • Percentage of Participants Who Achieved Dermatology Life Quality Index (DLQI) of 0 or 1 During Induction Period [ Time Frame: Week 4, 8, 12 ] [ Designated as safety issue: No ]
    The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.

  • Percentage of Participants Who Achieved Dermatology Life Quality Index (DLQI) of 0 or 1 During Maintenance Period [ Time Frame: Week 12,24,36, & 52 ] [ Designated as safety issue: No ]
    The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.

  • Percentage of Participants Achieving PASI 75, PASI 90 and IGA Mod 2011 0 or 1 Response at Week 12 by Previous Exposure to Biologic Systemic Therapy or Anti-TNF-α Therapy and Failed to Respond to a Previous Biologic or Anti-TNF-α Therapy Psoriasis Therapy [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    PASI is an assessment of lesion severity & affected area into a single score:0(no disease)to 72(max. disease).Body is divided into 4 areas for scoring(head,arms,trunk,legs)each area is scored separately & then added for final PASI.For each area, % of skin involved is estimated:0(0%)to 6(90-100%)& severity is estimated by clinical signs, erythema,induration & desquamation;scale 0(none) to 4(max). Final PASI=sum of severity parameters for each area* area score weight of section(head:0.1,arms:0.2 body:0.3 legs:0.4).PASI 75, 90 is patients achieving≥75%or90% improvement from baseline.The IGA mod 2011 scale is static, exclusively to the patients disease at assessment,& not with any of the patient's previous disease states at other visits.The scores are:0=clear,1=almost clear,2= mild,3=moderate&4=severe.Response variables PASI 75,90, IGA mod 2011 0 or 1 response at wk 12 was scored versus previous psoriasis systemic therapy & response to previous biologic systemic therapy by treatment

  • Number of Participants Who Developed Anti-secukinumab Antibodies [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    The development of anti-secunimubab anti-bodies would decrease a participant's ability to respond to secukinumab treatment.


Enrollment: 739
Study Start Date: June 2011
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AIN457 150 mg
AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week
Drug: secukinumab 150 mg
secukinumab (AIN457) 150mg or 300mg subcutaneous
Drug: placebo to secukinumab 150 mg
Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous
Experimental: AIN457 300 mg
AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week
Drug: secukinumab 150 mg
secukinumab (AIN457) 150mg or 300mg subcutaneous
Drug: placebo to secukinumab 150 mg
Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous
Placebo Comparator: placebo
placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
Drug: placebo to secukinumab 150 mg
Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous
Experimental: AIN457 150mg from Placebo
Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase because they were PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
Drug: secukinumab 150 mg
secukinumab (AIN457) 150mg or 300mg subcutaneous
Drug: placebo to secukinumab 150 mg
Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous
Experimental: AIN457 300mg from Placebo
Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase. PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
Drug: secukinumab 150 mg
secukinumab (AIN457) 150mg or 300mg subcutaneous
Drug: placebo to secukinumab 150 mg
Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Moderate and severe plaque-type psoriasis diagnosed for at least 6 months.
  • Severity of psoriasis disease meeting all of the following three criteria:
  • Psoriasis Area and Severity Index (PASI) score of 12 or greater,
  • Investigator's Global Assessment (IGA) score of 3 or greater,
  • Total body surface area (BSA) affected of 10% or greater.
  • Inadequate control by prior use of topical treatment, phototherapy and/or systemic therapy.

Exclusion criteria:

  • Current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate).
  • Current drug-induced psoriasis.
  • Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor.
  • Significant medical problems such as uncontrolled hypertension, congestive heart failure or a condition that significantly immunocompromises the subject.
  • Hematological abnormalities.
  • History of an ongoing, chronic or recurrent infectious disease, or evidence of untreated tuberculosis.
  • History of lymphoproliferative disease or history of malignancy of any organ system within the past 5 years.
  • Pregnant or nursing (lactating) women.
  • Subjects not willing to limit UV light exposure during the study Other protocol-defined inclusion/exclusion criteria may apply.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01365455

  Hide Study Locations
Locations
United States, Alabama
Novartis Investigative Site
Birmingham, Alabama, United States, 35205
Novartis Investigative Site
Birmingham, Alabama, United States, 35233
United States, Arizona
Novartis Investigative Site
Phoenix, Arizona, United States, 85032
United States, California
Novartis Investigative Site
Los Angeles, California, United States, 90045
Novartis Investigative Site
Oceanside, California, United States, 92056
Novartis Investigative Site
Pasadena, California, United States, 91105
Novartis Investigative Site
San Diego, California, United States, 92123
United States, Colorado
Novartis Investigative Site
Colorado Springs, Colorado, United States, 80915
United States, Florida
Novartis Investigative Site
Boca Raton, Florida, United States, 33486
United States, Georgia
Novartis Investigative Site
Snellville, Georgia, United States, 30078
United States, Indiana
Novartis Investigative Site
Evansville, Indiana, United States, 47713
United States, Kansas
Novartis Investigative Site
Topeka, Kansas, United States, 66606
United States, Kentucky
Novartis Investigative Site
Louisville, Kentucky, United States, 40291
Novartis Investigative Site
Louisville, Kentucky, United States, 40202
United States, Michigan
Novartis Investigative Site
Ann Arbor, Michigan, United States, 48109
Novartis Investigative Site
Ann Arbor, Michigan, United States, 48103
United States, Nebraska
Novartis Investigative Site
Omaha, Nebraska, United States, 68144
United States, New York
Novartis Investigative Site
New York, New York, United States, 10029
Novartis Investigative Site
Rochester, New York, United States, 14623
United States, Oregon
Novartis Investigative Site
Oregon City, Oregon, United States, 97045
Novartis Investigative Site
Portland, Oregon, United States, 97223
Novartis Investigative Site
Portland, Oregon, United States, 97210
United States, Pennsylvania
Novartis Investigative Site
Duncansville, Pennsylvania, United States, 16635
Novartis Investigative Site
Philadelphia, Pennsylvania, United States, 19104
United States, South Carolina
Novartis Investigative Site
Charleston, South Carolina, United States, 29407
United States, Tennessee
Novartis Investigative Site
Nashville, Tennessee, United States, 37203
United States, Texas
Novartis Investigative Site
Austin, Texas, United States, 78759
Novartis Investigative Site
Bryan, Texas, United States, 77802
Novartis Investigative Site
Dallas, Texas, United States, 75231
Novartis Investigative Site
Dallas, Texas, United States, 75246-1613
Novartis Investigative Site
Houston, Texas, United States, 77030
Novartis Investigative Site
San Antonio, Texas, United States, 78229
United States, Utah
Novartis Investigative Site
Salt Lake City, Utah, United States, 84117
United States, Virginia
Novartis Investigative Site
Norfolk, Virginia, United States, 23507
Argentina
Novartis Investigative Site
Caba, Buenos Aires, Argentina, C1425AWC
Novartis Investigative Site
Caba, Buenos Aires, Argentina, C1122AAF
Novartis Investigative Site
Caba, Buenos Aires, Argentina, C1181ACH
Novartis Investigative Site
Mendoza, Argentina, M5502EZA
Canada, New Brunswick
Novartis Investigative Site
Moncton, New Brunswick, Canada, E1C 8X3
Canada, Ontario
Novartis Investigative Site
Hamilton, Ontario, Canada, L8N 1V6
Novartis Investigative Site
Peterborough, Ontario, Canada, K9J 5K2
Novartis Investigative Site
Waterloo, Ontario, Canada, N2J 1C4
Canada, Quebec
Novartis Investigative Site
Montreal, Quebec, Canada, H3H 1V4
Colombia
Novartis Investigative Site
Barranquilla, Atlantico, Colombia
Novartis Investigative Site
Barranquilla, Colombia
Novartis Investigative Site
Bogotá, Colombia
Novartis Investigative Site
Bucaramanga, Colombia
Estonia
Novartis Investigative Site
Tallinn, Estonia, 10138
Novartis Investigative Site
Tallinn, Estonia, 10617
Novartis Investigative Site
Tallinn, Estonia, 13419
Novartis Investigative Site
Tartu, Estonia, 51014
Iceland
Novartis Investigative Site
Kopavogur, Iceland, IS-201
Israel
Novartis Investigative Site
Afula, Israel, 18101
Novartis Investigative Site
Petach Tikva, Israel, 49100
Novartis Investigative Site
Ramat Gan, Israel, 52621
Japan
Novartis Investigative Site
Nagoya-city, Aichi, Japan, 467-8602
Novartis Investigative Site
Fukuoka-city, Fukuoka, Japan, 814-0180
Novartis Investigative Site
Kurume, Fukuoka, Japan, 830-0011
Novartis Investigative Site
Maebashi-city, Gunma, Japan, 371-8511
Novartis Investigative Site
Asahikawa-city, Hokkaido, Japan, 078-8510
Novartis Investigative Site
Sapporo-city, Hokkaido, Japan, 060-0063
Novartis Investigative Site
Kobe-City, Hyogo, Japan, 654-0155
Novartis Investigative Site
Inashiki-gun, Ibaraki, Japan, 300-0395
Novartis Investigative Site
Isehara-city, Kanagawa, Japan, 259-1193
Novartis Investigative Site
Kawasaki-city, Kanagawa, Japan, 213-8507
Novartis Investigative Site
Sagamihara-city, Kanagawa, Japan, 228-8522
Novartis Investigative Site
Bunkyo-ku, Tokyo, Japan, 113-8655
Novartis Investigative Site
Chiyoda-ku, Tokyo, Japan, 102-8798
Novartis Investigative Site
Minato-ku, Tokyo, Japan, 105-8471
Novartis Investigative Site
Shinagawa-ku, Tokyo, Japan, 141-8625
Novartis Investigative Site
Shinjuku-ku, Tokyo, Japan, 160-0023
Novartis Investigative Site
Shinjuku-ku, Tokyo, Japan, 160-8582
Novartis Investigative Site
Kyoto, Japan, 602-8566
Latvia
Novartis Investigative Site
Daugavpils, Latvia, LV-5404
Novartis Investigative Site
Riga, Latvia, LV-1001
Novartis Investigative Site
Riga, Latvia, 1012
Novartis Investigative Site
Ventspils, Latvia, LV-3601
Lithuania
Novartis Investigative Site
Kaunas, Lithuania, 50009
Novartis Investigative Site
Klaipeda, Lithuania, 92304
Novartis Investigative Site
Vilnius, Lithuania, LT-07195
Novartis Investigative Site
Vilnius, Lithuania, LT-08661
Mexico
Novartis Investigative Site
México, Distrito Federal, Mexico, 06780
Novartis Investigative Site
México, Distrito Federal, Mexico, 14050
Novartis Investigative Site
Zapopan, Jalisco, Mexico, 45190
Novartis Investigative Site
Monterrey, Nuevo León, Mexico, 64460
Taiwan
Novartis Investigative Site
Hsin Chu, Taiwan
Novartis Investigative Site
Taichung, Taiwan, 40447
Novartis Investigative Site
Taipei, Taiwan, 10002
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Study Director: Novartis Pharmceuticals Novartis Pharmaceuticals
  More Information

No publications provided by Novartis

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT01365455     History of Changes
Other Study ID Numbers: CAIN457A2302, 2010-023512-13
Study First Received: June 1, 2011
Results First Received: February 16, 2015
Last Updated: May 7, 2015
Health Authority: United States: Food and Drug Administration
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Canada: Health Canada
Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos
Estonia: The State Agency of Medicine
Iceland: Icelandic Medicines Control Agency
Israel: Ministry of Health
Japan: Ministry of Health, Labor and Welfare
Latvia: State Agency of Medicines
Lithuania: State Medicine Control Agency - Ministry of Health
Mexico: Federal Commission for Sanitary Risks Protection
Panama: Ministry of Health
Peru: Ministry of Health
Russia: Ministry of Health of the Russian Federation
Taiwan: Department of Health

Keywords provided by Novartis:
Psoriasis
plaque
plaque-type psoriasis
IL-17 blocker
subcutaneous
psoriatic arthritis
injection
AIN457
AIN457A
secukinumab

Additional relevant MeSH terms:
Psoriasis
Skin Diseases
Skin Diseases, Papulosquamous
Antibodies, Monoclonal
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 27, 2015